VA-DXC-TECHNOLOGY
29.4.2021 14:07:06 CEST | Business Wire | Press release
DXC Technology (NYSE: DXC) announced today that Zurich Insurance Group (Zurich) has extended its agreement with DXC to provide IT and security services over the next five years as a vital component of the company’s IT transformation. This applications-led infrastructure and application modernization will help Zurich improve its overall customer and employee experience.
As part of the enhanced agreement, Zurich will leverage DXC capabilities across the Enterprise Technology Stack . This will provide Zurich with the ability to deploy applications faster through automation, helping them to introduce new products quickly and at scale, and to improve operational resiliency.
“We put our customers’ needs at the center of everything we do. Enhancing and automating our core insurance processes will help us to provide customers with a better experience, whether they purchase a new insurance policy or are filing a claim,” said Daniel Englberger, Chief Operating Officer, Group Technology & Operations, Zurich Insurance Group. “DXC’s IT and security services, as well as the joint applications-led infrastructure modernization initiative, will contribute to the overall framework powering our digitization strategy.”
“Zurich is a valued DXC customer and we welcome the opportunity to be part of the company’s global transformational journey,” said Mike Salvino, President and CEO, DXC Technology. “We listened carefully to Zurich’s needs and are excited to deliver our capabilities across the Enterprise Technology Stack to benefit the company, its people and customers.”
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy the Enterprise Technology Stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology .
About Zurich Insurance Group
Zurich is a leading multi-line insurer that serves its customers in global and local markets. With about 55,000 employees, it provides a wide range of property and casualty, life insurance products and services in more than 215 countries and territories. Zurich’s customers include individuals, small businesses, and mid-sized and large companies, as well as multinational corporations. For more information visit: www.zurich.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005621/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Together AI and HUMAIN Form Strategic Partnership to Accelerate AI Infrastructure and Cloud Services in Saudi Arabia31.8.2026 14:00:00 CEST | Press release
The partnership, which was announced on stage at LEAP, Combines HUMAIN’s AI Infrastructure Foundation with Together’s AI Native Cloud Platform and Global Reach Together AI, a leading San Francisco-based AI Native Cloud platform, and HUMAIN, a PIF company delivering full-stack artificial intelligence capabilities globally, today at LEAP announced a strategic partnership to connect HUMAIN’s rapidly expanding AI compute capacity in Saudi Arabia with global AI-native and enterprise demand. The partnership will include the construction of a new 250 megawatt data center, located in Saudi Arabia. The partnership brings together HUMAIN’s large-scale, multi-chip AI infrastructure footprint, expanding cloud and inference capabilities with Together AI’s global customer ecosystem and AI-native inference platform. Together, the companies will offer an additional option for developers, enterprises, and AI-native organizations worldwide to access high-performance AI infrastructure for inference and t
SLB to Acquire Kelvion, Expanding its Role Across Data Center Infrastructure31.8.2026 12:50:00 CEST | Press release
Scalable, energy-efficient and reliable thermal management technologies will optimize operating performance in increasingly complex data centers and industrial systems SLB (NYSE: SLB) today announced it has signed an agreement to acquire Kelvion, a global provider of thermal management and heat exchange technologies. The acquisition strengthens SLB's Data Center Solutions business with critical thermal management technologies and expands the company's role in data center infrastructure, which is one of the world’s fastest-growing industrial and technology markets. “AI is driving the most significant infrastructure investment cycle in our lifetime,” said Olivier Le Peuch, chief executive officer of SLB. “This transaction accelerates our ambition to become an industrial technology partner to the data center industry and help customers address the growing infrastructure complexity required to scale AI. Kelvion advances our path toward more integrated data center infrastructure solutions,
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom